Form 8-K Galena Biopharma, Inc. For: Mar 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Form 8-K Galena Biopharma, Inc. For: Mar 05
March 6, 2015 8:42 AM EST
Roth Capital reiterates its Buy rating and $8 price target on Galena Biopharma (Nasdaq: GALE) following Q4, FY14 results reported Thursday night.
Analyst Joseph Pantginis noted that Galena's FY14 revenue of $9.32 million and loss of $0.31 per share compare with the firm's outlook calling for revenue of $8.5 million and loss of $0.35 per share.
Pantginis offered the following post-report commentary: 2015 represents a... More
March 5, 2015 4:21 PM EST
Galena Biopharma (NASDAQ: GALE) reported Q4 EPS of ($0.06), may not compare to the analyst estimate of ($0.11). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $2.58 million.
Galena reiterated 2015 net revenue guidance between $15-$18 million for the combined commercial... More
